B-cell Lymphoma Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, B-cell Lymphoma pipeline constitutes 295+ key companies continuously working towards developing 300+ B-cell Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"B-cell Lymphoma Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the B-cell Lymphoma Market.

The B-cell Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the B-cell Lymphoma Pipeline Report: https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel B-cell Lymphoma treatment therapies with a considerable amount of success over the years.
• B-cell Lymphoma companies working in the treatment market are Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Autolus Limited, SystImmune Inc, Hanmi Pharmaceutical, Xynomic Pharmaceuticals, Pfizer, ZAI Lab, Oncternal Therapeutics, Pfizer, Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics, Inc., and others, are developing therapies for the B-cell Lymphoma treatment
• Emerging B-cell Lymphoma therapies in the different phases of clinical trials are- VIP 924, UBX-303-1, BMF-219, SHR-A1912, Ociperlimab, AUTO3, GNC-038, Poseltinib, Abexinostat, PF-07901801, Odronextamab, Zilovertamab, PF-07901801, LP-168, TG-1801, and others are expected to have a significant impact on the B-cell Lymphoma market in the coming years.
• In September 2025, Lyell Immunopharma (CA, USA) has launched the first-ever Phase III trial directly comparing CAR T-cell therapies for large B-cell lymphoma (LBCL). Meanwhile, BlueWhale Bio (PA, USA) has treated its first patient with a cell therapy powered by its proprietary SynectaTM T1 CDNPs (cell-derived nanoparticles) platform. In addition, Mytos (London, UK) revealed three new partnerships focused on advancing cell therapy manufacturing
• In July 2025, Findings from the Phase Ib study (NCT03666000) revealed that Imugene's azer-cel (azercabtagene zapreleucel), an off-the-shelf allogeneic CAR-T therapy, showed strong potential in treating patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Based on these encouraging results and the therapy's Fast Track Designation received in March, the company plans to pursue a Type B meeting with the FDA in Q4 to discuss the design of a registrational trial.
• In June 2025, Lyell Immunopharma has shared updated clinical results from its Phase I/II trial evaluating LYL314, an autologous dual-target CD19/CD20 CAR T-cell therapy, including findings in patients with large B-cell lymphoma (LBCL) who had received at least three prior lines of treatment. Among 25 patients in the 3L+ group, the therapy demonstrated an 88% overall response rate (ORR) and a 72% complete response rate (CRR). Impressively, 71% of patients who achieved a complete response maintained it for at least six months. The PiNACLE study, which continues to assess LYL314 in relapsed or refractory LBCL in the 3L+ setting, is currently ongoing.
• In January 2025, Imugene, an Australian immuno-oncology company, has initiated dosing for the first Australian participant in its Phase Ib clinical trial of the allogeneic CAR T-cell therapy, azer-cel (azercabtagene zapreleucel). The trial aims to evaluate the therapy's potential in managing relapsed or refractory diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin's lymphoma.
• In December 2024, AbbVie (NYSE: ABBV) announced new data from two ongoing clinical trials evaluating epcoritamab, a subcutaneous CD3xCD20 bispecific T-cell engager, in adults with diffuse large B-cell lymphoma (DLBCL). The findings were shared at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH). One part of the Phase 1b/2 EPCORE® NHL-2 multi-arm study (Arm 1) is testing a fixed-duration regimen of epcoritamab in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in previously untreated high-risk DLBCL patients (n=46) with International Prognostic Index (IPI) scores of 3-5 (Abstract #581).
• In November 2024, Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage biotechnology company developing next-generation CAR T-cell therapies for solid tumors and hematologic cancers, announced that preliminary clinical data from the Phase 1-2 trial of IMPT-314 in large B-cell lymphoma will be featured at the 66th American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA, from December 7 to 10, 2024. The presentation will be delivered by Dr. Sarah M. Larson, Associate Professor of Medicine and Medical Director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at UCLA's David Geffen School of Medicine.

B-cell Lymphoma Overview
B-cell Lymphoma is a cancer originating from B cells, a crucial component of the immune system. This type of lymphoma can manifest as either slow-growing (indolent) or fast-growing (aggressive). Generally, most B-cell lymphomas belong to the category of non-Hodgkin lymphomas. Within this classification, there exist numerous diverse types of B-cell non-Hodgkin lymphomas.

Get a Free Sample PDF Report to know more about B-cell Lymphoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/b-cell-lymphomas-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging B-cell Lymphoma Drugs Under Different Phases of Clinical Development Include:
• VIP 924: Vincerx Pharma
• UBX-303-1: Ubix Therapeutics
• BMF-219: Biomea Fusion Inc.
• SHR-A1912: Shanghai Hengrui Pharmaceutical
• Ociperlimab: BeiGene
• AUTO3: Autolus Limited
• GNC-038: SystImmune Inc
• Poseltinib: Hanmi Pharmaceutical
• Abexinostat: Xynomic Pharmaceuticals
• PF-07901801: Pfizer
• Odronextamab: ZAI Lab
• Zilovertamab: Oncternal Therapeutics
• PF-07901801: Pfizer
• LP-168: Guangzhou Lupeng Pharmaceutical Company LTD.
• TG-1801: TG Therapeutics, Inc.

B-cell Lymphoma Route of Administration
B-cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

B-cell Lymphoma Molecule Type
B-cell Lymphoma Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

B-cell Lymphoma Pipeline Therapeutics Assessment
• B-cell Lymphoma Assessment by Product Type
• B-cell Lymphoma By Stage and Product Type
• B-cell Lymphoma Assessment by Route of Administration
• B-cell Lymphoma By Stage and Route of Administration
• B-cell Lymphoma Assessment by Molecule Type
• B-cell Lymphoma by Stage and Molecule Type

DelveInsight's B-cell Lymphoma Report covers around 300+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further B-cell Lymphoma product details are provided in the report. Download the B-cell Lymphoma pipeline report to learn more about the emerging B-cell Lymphoma therapies
https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the B-cell Lymphoma Therapeutics Market include:
Key companies developing therapies for B-cell Lymphoma are - Oncternal Therapeutics, Inc, ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, and others.

B-cell Lymphoma Pipeline Analysis:
The B-cell Lymphoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of B-cell Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-cell Lymphoma Treatment.
• B-cell Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• B-cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the B-cell Lymphoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about B-cell Lymphoma drugs and therapies
https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

B-cell Lymphoma Pipeline Market Drivers
• Increase in prevalence of B-cell Lymphoma, launch of several novel therapies for treating B cell Lymphoma are some of the important factors that are fueling the B-cell Lymphoma Market.

B-cell Lymphoma Pipeline Market Barriers
• However, high cost of the treatment, side effects associated with the therapies and other factors are creating obstacles in the B-cell Lymphoma Market growth.

Scope of B-cell Lymphoma Pipeline Drug Insight
• Coverage: Global
• Key B-cell Lymphoma Companies: Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Autolus Limited, SystImmune Inc, Hanmi Pharmaceutical, Xynomic Pharmaceuticals, Pfizer, ZAI Lab, Oncternal Therapeutics, Pfizer, Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics, Inc., and others
• Key B-cell Lymphoma Therapies: VIP 924, UBX-303-1, BMF-219, SHR-A1912, Ociperlimab, AUTO3, GNC-038, Poseltinib, Abexinostat, PF-07901801, Odronextamab, Zilovertamab, PF-07901801, LP-168, TG-1801, and others
• B-cell Lymphoma Therapeutic Assessment: B-cell Lymphoma current marketed and B-cell Lymphoma emerging therapies
• B-cell Lymphoma Market Dynamics: B-cell Lymphoma market drivers and B-cell Lymphoma market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.